• Publications
    Expected Returns Articles
  • Research
    Companies Funds Top 40 My Studies
  • Stock Screen
    New Stock Screen Manage Screens
  • Dashboards
    My Dashboards New Dashboard
  • Forum
  • Events
  • Search
  • Contact Us
  • Sign In

Strength In Numbers

Cover Story, by Mark Robertson, Managing Partner July 1st, 2015


“It’s about creating strength in numbers ... finding common ground ... and supporting each other.” -- Jane Kim.

Bio-Reference Labs (BRLI). This relatively obscure real life CSI story has been a fairly dramatic example of discovery, diligence and stewardship over the last several years. Likely uncovered during our annual forensic review of the Forbes Best Small Companies, Bio-Reference Labs has been something of a roller coaster (when it comes to stock price) and a rock (when it comes to fundamentals.) The assaults by short sellers are legend and the common ground shoulder-to-shoulder support offered by our community of investors is even more legendary. So we celebrate … and shop.

It’s something of the end of an era.

The announcement of the merger between Bio-Reference Labs (BRLI) and Opko Health (OPK) is something of mixed blessing for a number of investors. Yes, the 30-40% sudden surge in the stock price of BRLI is welcome. But the widely expected overall condition of the newly formed combination is suspect. Many BRLI shareholders are justifiably skeptical and will tender their shares, capturing a fairly decent return over these last few years.

And a new hunt begins.

We doubt that Opko Health will remain among the MANIFEST 40 when the dust settles. Make no mistake. We will miss Bio-Reference Labs. From discovery (see Solomon Select, December 2010) to the events of the last month, we’ve collectively watched and supported fellow investors during assaults by short sellers and their gloom and doom attacks on BRLI. The Forum folders have a multitude of posts on the company — including some personal face-to-face highlights of interviews with CEO Mark Grodman delivered by one of our subscribers while attending a few annual meetings. Thanks, Nick DiVirglio!

A Place Where Ideas Are Born

Apple (AAPL) continues at the top of the leader board, a position the company has held for several months. AAPL first appeared on this listing on 9/24/2009 and proceeded to ascend to the summit. Johnson & Johnson (JNJ) and AFLAC (AFL) traded places at #5 and #6. Fastenal (FAST) jumped from #9 to #7 and Bio-Reference Labs has started the virtually certain migration off the chart.

It bears repeating. In addition to Bio-Reference Labs, both Apple and Cognizant Technology (CTSH) were not among the charter members of this manifest. Both AAPL and CTSH were added about 4-5 years after inception as subscribers featured both companies on dashboards during a period of continued strong quality that was accompanied by attractive prices for a fairly extended period.

MANIFEST 40 Most Widely-Followed Stocks (6/30/2015). Current leader Apple (AAPL) was added to the list on 9/24/2009 and has generated a relative return of +26.2% (annualized) since then. Figures in parentheses are the ranking from March 2015.

Performance Results

The strong historical performance persists. The average annualized RELATIVE return for the current tracking portfolio is +3.5%. (The rate of return for the tracking portfolio since inception is 9.9% over 9.75 years.)

The accuracy rating (% of outperforming entries) of the current selections is 64%.

The figures in parentheses are the position of the company during the March 2015 listing of the MANIFEST 40. For example, T. Rowe Price (TROW) advanced from #40 to #37 over the last three months.

Chargers and Newcomers

Bio-Reference Labs was a newcomer, first reaching the list back in December 2010. The company also ranked as a “charger” typified by a company making the strongest advances up the ranking on a quarter-to-quarter basis. This may be indicative of strong fundamentals (combined with attractive prices and return forecasts) and probably warrants further study.

Gilead Sciences (GILD) rejoins the MANIFEST 40 at #36. GILD is worthy of careful study by investors.

While not a typical surge demonstrated by a charger, Fastenal did move from #9 to #7 — solidifying its position among our favorites. As mentioned, T. Rowe Price (TROW) did make an advance from the bottom of the list and continues to deliver strong performance.

It’s a high quality list and can be used for “shopping” via:

https://www.manifestinvesting.com/dashboards/public/manifest-40

What stock will we be celebrating five years from now that isn’t currently on the list? Place your bets. Share your ideas. Uncommon ground.

Mark Robertson

Mark Robertson is founder and managing partner of Manifest Investing, a source for research and portfolio management focusing on strategic long term investors.

Expected Returns, Jul 2015
  • Strength In Numbers
  • Apple
  • Hoard vs. Herds
  • Sweet 16
  • Tin Cup Model Portfolio
  • Measuring Performance Results
Opko Health (OPK)
Quality 7
PAR 13.8%
Apple (AAPL)
Quality 98
PAR 8.5%
Cognizant Technology (CTSH)
Quality 77
PAR 9.7%
Price T. Rowe (TROW)
Quality 78
PAR 15.9%
Gilead Sciences (GILD)
Quality 62
PAR 9.0%
Join Manifest Investing

Manifest is an easy to use resource for your investing.

Create dashboards, research companies, discuss your ideas on the forum, and get insight into long-term investing.


Learn More Get Started

© 2006 - 2025 Manifest Investing. All rights reserved.
About | Terms of Service | Disclaimer | Privacy Policy

Legend
Quality Legend:
Blue Excellent with quality greater than 80.
Green Good with quality between 60 and 80.
Neutral Average or below average with quality between 20 and 60.
Red Poor with quality less than 20.
Companies with less than 10 years of history are penalized by 5 points per year.
PAR Legend:
Green PAR is within the target range of MIPAR +5-10%, currently 5.1%-10.1%
Yellow PAR is above the target range of MIPAR +10%, currently 10.1%
PAR Projected Annual Return
MIPAR The Manifest Investing Median PAR of all stocks in the database.
Company Name Legend:
* Not covered by Value Line Standard Edition.
b Uses price-to-book value for valuation purposes.
P/CF Uses price-to-cash flow for valuation.